PD-L1 assessment in lung cancer biopsies—pitfalls and limitations

The programmed cell death-ligand 1 (PD-L1) protein expression on tumor cells predicts the efficacy of immunotherapy in patients with non-small cell lung cancer. However, the assessment of PD-L1 expression on tumor cells has limited power for selecting patients for immunotherapy due to intra-tumoral...

Full description

Saved in:
Bibliographic Details
Published in:The International Journal of Biological Markers 2024-03, Vol.39 (1), p.3-8
Main Authors: Gompelmann, Daniela, Sarova, Pavla, Mosleh, Berta, Papaporfyriou, Anastasia, Oberndorfer, Felicitas, Idzko, Marco, Hoda, Mir Alireza
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Biopsy
Cell death
Immunotherapy
Lung cancer
Non-small cell lung carcinoma
PD-L1 protein
Small cell lung carcinoma
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The programmed cell death-ligand 1 (PD-L1) protein expression on tumor cells predicts the efficacy of immunotherapy in patients with non-small cell lung cancer. However, the assessment of PD-L1 expression on tumor cells has limited power for selecting patients for immunotherapy due to intra-tumoral heterogeneity and inter-tumoral heterogeneity of PD-L1 expression, the inter-observer variability in scoring PD-L1 staining, and reproducibility. These difficulties and pitfalls in interpreting the PD-L1 assessment are discussed in detail in this review.
ISSN:0393-6155
1724-6008
DOI:10.1177/03936155231214273